Company Profile
BrightGene Bio-Medical Technology researches, develops, produces, and sells pharmaceutical products in China and globally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development formulations. Its portfolio also includes preparation products, active pharmaceutical ingredients and intermediates, and veterinary drugs for various therapeutic areas
Including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others.
Additionally, it is involved in technology R&D. Its portfolio also includes transfer of biomedical products, import, export, wholesale, and retail of medicines, production and operation of medical devices, and technical services. Founded in 2001, BrightGene Bio-Medical Technology is based in Suzhou, China.